{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:58:18Z","timestamp":1785200298651,"version":"3.55.0"},"reference-count":50,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2020,12,11]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Radionuclide imaging remains an essential component of modern cardiology. There is overlap with the information from other imaging techniques, but no technique is static and new developments have expanded its role. This review focuses on ischaemic heart disease, heart failure, infection and inflammation. Radiopharmaceutical development includes the wider availability of positron emission tomography (PET) tracers such as rubidium-82, which allows myocardial perfusion to be quantified in absolute terms. Compared with alternative techniques, myocardial perfusion scintigraphy PET and single photon emission computed tomography (SPECT) have the advantages of being widely applicable using exercise or pharmacological stress, full coverage of the myocardium and a measure of ischaemic burden, which helps to triage patients between medical therapy and revascularisation. Disadvantages include the availability of expertise in some cardiac centres and the lack of simple SPECT quantification, meaning that global abnormalities can be underestimated. In patients with heart failure, despite the findings of the STICH (Surgical Treatment for Ischemic Heart Failure) trial, there are still data to support the assessment of myocardial hibernation in predicting when abolition of ischaemia might lead to improvement in ventricular function. Imaging of sympathetic innervation is well validated, but simpler markers of prognosis mean that it has not been widely adopted. There are insufficient data to support its use in predicting the need for implanted devices, but non-randomised studies are promising. Other areas where radionuclide imaging is uniquely valuable are detection and monitoring of endocarditis, device infection, myocardial inflammation in sarcoidosis, myocarditis and so on, and reliable detection of deposition in suspected transthyretin-related amyloidosis.<\/jats:p>","DOI":"10.1136\/heartjnl-2019-315628","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T16:34:56Z","timestamp":1611333296000},"page":"954-961","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Nuclear cardiology: state of the art"],"prefix":"10.1136","volume":"107","author":[{"given":"Rebecca","family":"Schofield","sequence":"first","affiliation":[{"name":"Department of Cardiology, North West Anglia NHS Foundation Trust, Peterborough, Cambridgeshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Menezes","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-1442","authenticated-orcid":false,"given":"Stephen Richard","family":"Underwood","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"2025100705100689000_107.12.954.1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001186"},{"key":"2025100705100689000_107.12.954.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-0998-8"},{"key":"2025100705100689000_107.12.954.3","doi-asserted-by":"publisher","DOI":"10.1186\/2197-7364-1-9"},{"key":"2025100705100689000_107.12.954.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3139-x"},{"key":"2025100705100689000_107.12.954.5","article-title":"Added value of myocardial blood flow using \n                  18\n               F-flurpiridaz PET to diagnose coronary artery disease: The flurpiridaz 301 trial","author":"Moody","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2025100705100689000_107.12.954.6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12350-017-1110-x","article-title":"Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI cardiovascular Council and the ASNC","volume":"25","author":"Murthy","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"2025100705100689000_107.12.954.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.011939"},{"key":"2025100705100689000_107.12.954.8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/eurheartj\/ehz389","article-title":"Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization","volume":"41","author":"Patel","year":"2020","journal-title":"Eur Heart J"},{"key":"2025100705100689000_107.12.954.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023266"},{"key":"2025100705100689000_107.12.954.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1344-5"},{"key":"2025100705100689000_107.12.954.11","unstructured":". Available: https:\/\/www.nice.org.uk\/guidance\/cg95\/chapter\/Update-information [Accessed 10\/03\/2020]."},{"key":"2025100705100689000_107.12.954.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915922"},{"key":"2025100705100689000_107.12.954.13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamacardio.2020.0822","article-title":"Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia: secondary analysis of the ischemia randomized clinical trial","volume":"5","author":"Reynolds","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025100705100689000_107.12.954.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq500"},{"key":"2025100705100689000_107.12.954.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.055"},{"key":"2025100705100689000_107.12.954.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415516"},{"key":"2025100705100689000_107.12.954.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805971"},{"key":"2025100705100689000_107.12.954.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61754-7"},{"key":"2025100705100689000_107.12.954.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.060"},{"key":"2025100705100689000_107.12.954.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)33095-5"},{"key":"2025100705100689000_107.12.954.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.03.012"},{"key":"2025100705100689000_107.12.954.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100358"},{"key":"2025100705100689000_107.12.954.23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa1807365","article-title":"Myocardial viability and long-term outcomes in ischemic cardiomyopathy","volume":"381","author":"Panza","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100705100689000_107.12.954.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.006"},{"key":"2025100705100689000_107.12.954.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.065938"},{"key":"2025100705100689000_107.12.954.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2009.02.017"},{"key":"2025100705100689000_107.12.954.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004331"},{"key":"2025100705100689000_107.12.954.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.014"},{"key":"2025100705100689000_107.12.954.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.12.066"},{"key":"2025100705100689000_107.12.954.30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijcard.2017.08.003","article-title":"Cardiac \n                  123\n               I-mIBG scintigraphy is associated with freedom of appropriate ICD therapy in stable chronic heart failure patients","volume":"248","author":"Verschure","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025100705100689000_107.12.954.31","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"Esc guidelines for the management of infective endocarditis","volume":"2015","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"2025100705100689000_107.12.954.32","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1093\/eurheartj\/ehz620","article-title":"Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study","volume":"40","author":"Habib","year":"2019","journal-title":"Eur Heart J"},{"key":"2025100705100689000_107.12.954.33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2017.10.116","article-title":"Molecular imaging for the diagnosis of infective endocarditis: a systematic literature review and meta-analysis","volume":"253","author":"Juneau","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025100705100689000_107.12.954.34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.118.007626"},{"key":"2025100705100689000_107.12.954.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2013.08.001"},{"key":"2025100705100689000_107.12.954.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.01.025"},{"key":"2025100705100689000_107.12.954.37","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025100705100689000_107.12.954.38","first-page":"89","article-title":"Diagnostic standard and guidelines for sarcoidosis","volume":"27","author":"Hiraga","year":"2007","journal-title":"Jpn J Sarcoidosis Granulomatous Disord"},{"key":"2025100705100689000_107.12.954.39","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.4.1372"},{"key":"2025100705100689000_107.12.954.40","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-007-0060-9"},{"key":"2025100705100689000_107.12.954.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.03.043"},{"key":"2025100705100689000_107.12.954.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.022"},{"key":"2025100705100689000_107.12.954.43","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-013-9828-6"},{"key":"2025100705100689000_107.12.954.44","doi-asserted-by":"crossref","unstructured":"Chen W , Dilsizian V . Molecular imaging of amyloid deposits for early diagnosis of cardiac amyloidosis and monitoring treatment response. JACC: Cardiovascular Imaging, 2020. (accessed 2020-05-26).","DOI":"10.1016\/j.jcmg.2020.02.026"},{"key":"2025100705100689000_107.12.954.45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025100705100689000_107.12.954.46","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2025100705100689000_107.12.954.47","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2019.08.002","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Card Fail"},{"key":"2025100705100689000_107.12.954.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"2025100705100689000_107.12.954.49","first-page":"195","article-title":"99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis","volume":"6","author":"Bokhari","year":"2013","journal-title":"Clinical Perspective. Circ Cardiovasc Imaging"},{"key":"2025100705100689000_107.12.954.50","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2019-315628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:16:31Z","timestamp":1759839391000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2019-315628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,5,26]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/heartjnl-2019-315628"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2019-315628","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}